Skip Page Header

Home > Cannabinoid type 1 receptor antagonists for smoking cessation.

Cahill, Kate and Ussher, Michael H [The Cochrane Library] . (2011) Cannabinoid type 1 receptor antagonists for smoking cessation. London: John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews (3) Art. No.: CD005353. DOI: 10.1002/14651858.CD005353.pub4.

URL: http://onlinelibrary.wiley.com/doi/10.1002/1465185...

Objectives:
• To determine whether selective CB1 receptor antagonists (currently rimonabant and taranabant) increase the numbers of people stopping smoking
• To assess their effects on weight change in successful quitters and in those who try to quit but fail.

Conclusions: From the trial reports available, rimonabant 20 mg may increase the chances of quitting approximately 1½-fold. The evidence for rimonabant in maintaining abstinence is inconclusive. Rimonabant 20 mg may moderate weight gain in the long term. Taranabant 2-8 mg may moderate weight gain, at least in the short term. In 2008, development of both rimonabant and taranabant was discontinued by the manufacturers.


Item Type
Evidence resource
Publication Type
Review
Drug Type
Tobacco
Intervention Type
AOD disorder drug therapy
Date
2011
Publisher
John Wiley & Sons, Ltd
Place of Publication
London
Number
3
EndNote
Accession Number
HRB (Not in collection)

Repository Staff Only: item control page